Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4878901 | 0.90 | POLB (0.34) | POLBL3MBTL1 | |
| SCHEMBL4664823 | 0.90 | POLB (0.34) | POLBL3MBTL1 | |
| SCHEMBL4659074 | 0.77 | KDM4E (0.33) | ALDH1A1KDM4ECHRM1 | |
| SCHEMBL27088837 | 0.75 | CYP1A2 (0.34) | POLBL3MBTL1ALDH1A1KDM4E | |
| SCHEMBL5074496 | 0.74 | CHRNB2 (0.31) | — | |
| SCHEMBL4946594 | 0.73 | ALDH1A1 (0.34) | LMNAALDH1A1 | |
| SCHEMBL20144886 | 0.73 | POLB (0.47) | POLBL3MBTL1LMNAALDH1A1 | |
| SCHEMBL4385122 | 0.73 | POLB (0.47) | POLBL3MBTL1LMNAALDH1A1 | |
| SCHEMBL4760346 | 0.70 | — | — | |
| SCHEMBL20144697 | 0.69 | L3MBTL1 (0.47) | POLBL3MBTL1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312240-A1 | Bicyclic Piperazines as Metabotropic Glutatmate Receptor Antagonists | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080194571-A1 | Acetylenic Piperazines as Metabotropic Glutamate Receptor Antagonists | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | US | disclosed |
| EP-1919915-A2 | ACETYLENIC PIPERAZINES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007021575-A2 | ACETYLENIC PIPERAZINES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037816-A1 | Bicyclic piperazines as metabotropic glutatmate receptor antagonists | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037817-A1 | Acetylenic piperazines as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312240-A1 | Bicyclic Piperazines as Metabotropic Glutatmate Receptor Antagonists | GRM5, GRM1, GRIN1 | POLB 4478/4885L3MBTL1 3673/4885LMNA 4118/4885 |
| US-20070037817-A1 | Acetylenic piperazines as metabotropic glutamate receptor antagonists | GRM1, GRM5, GRIN1 | POLB 3616/4885L3MBTL1 3684/4885LMNA 4217/4885 |
| US-20080194571-A1 | Acetylenic Piperazines as Metabotropic Glutamate Receptor Antagonists | GRM1, GRM5, GRIN1 | POLB 3616/4885L3MBTL1 3684/4885LMNA 4217/4885 |
| US-20070037816-A1 | Bicyclic piperazines as metabotropic glutatmate receptor antagonists | GRM5, GRM1, GRIN1 | POLB 4478/4885L3MBTL1 3673/4885LMNA 4118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.